Summary of single and multiple treatment models
| Source (figure) | Ranibizumab | Bevacizumab | Ratio | |||||
| Time to minimum (days) | Loss of effect (days) | r2 | Time to minimum (days) | Loss of effect (days) | r2 | |||
| Multiple treatment | ||||||||
| Model of first treatment | 4 | 28.1 | 56.3 | 0.95 | 45.1 | 90.1 | 0.73 | 1.60 |
| Model of second treatment | 4 | 29.7 | 59.3 | 0.81 | 45.1 | 90.2 | 0.57 | 1.52 |
| Single treatment | ||||||||
| Macular volume (exponential) | 3 | 43.0 | 86.0 | 0.75 | 50.7 | 101.4 | 0.91 | 1.18 |
| Macular volume (quadratic) | 2 | 47.3 | 94.6 | 0.83 | 62.7 | 125.4 | 0.82 | 1.33 |
| Summary statistics | ||||||||
| Mean (SD) | 37.0 (9.6) | 74.0 (19.1) | 50.9 (8.3) | 101.8 (16.6) | 1.40 (0.19) | |||
Coefficient of determination (r2), the days required to achieve minimal macular volume and the duration of action are shown. Time required to achieve a maximal reduction in macular volume ranged from 28.1 to 47.3 days for ranibizumab (mean = 37.0 (9.6) days) versus 45.1 to 62.7 days for bevacizumab (mean = 50.9 (8.3) days), and the duration of action ranged from 56.3 to 94.6 days for ranibizumab (mean = 74.0 (19.1) days) versus 90.1 to 125.4 for bevacizumab (mean = 101.8 (16.6) days). The relative duration of action of bevacizumab was consistently longer than the duration of action of ranibizumab (last column) (range = 1.18 to 1.60; mean = 1.40 (0.19)).